Literature DB >> 3998738

Thymectomy in myasthenia with pure ocular symptoms.

F Schumm, H Wiethölter, A Fateh-Moghadam, J Dichgans.   

Abstract

Eighteen patients with exclusively ocular symptoms of myasthenia were thymectomised. Suspected thymoma, resistance to pyridostigmine therapy or relapse following immunosuppressive therapy were taken as indications for surgery. The mean preoperative observation period before operation was 40 months, and after operation was 26 months. There was no operative or postoperative morbidity or mortality. Histological thymic abnormalities were found in all patients (in one case, thymoma; in four, persistent thymus; in 13, thymic hyperplasia). The histological abnormalities were identical to those found in generalised myasthenia. This included the distribution of T-cell subtypes as identified by use of monoclonal antibodies. The severity of ocular symptoms was rated using a score developed for this purpose. The score progressively declined after surgery to an average of 70% of its initial amount in 80% of patients. Full remission occurred in three cases. No patient developed generalized myasthenia. Antibody titres against acetylcholine receptors if elevated preoperatively also dropped following surgery, with one exception. Clear criteria for the expected therapeutic success of thymectomy could not be identified. Based on our results, and on the assumed significance of the thymus gland for pathogenesis, thymectomy should be considered in patients with pure ocular symptoms.

Entities:  

Mesh:

Year:  1985        PMID: 3998738      PMCID: PMC1028297          DOI: 10.1136/jnnp.48.4.332

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations.

Authors:  G Genkins; A E Papatestas; S H Horowitz; P Kornfield
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

Review 2.  Thymectomy in myasthenia gravis: pathologic, clinical, and electrophysiologic correlations.

Authors:  A E Papatestas; G Genkins; S H Horowitz; P Kornfeld
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

3.  Accessory nerve stimulation in the assessment of myasthenia gravis.

Authors:  F Schumm; M Stöhr
Journal:  Muscle Nerve       Date:  1984-02       Impact factor: 3.217

4.  Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis.

Authors:  H Wekerle; R Hohlfeld; U P Ketelsen; J R Kalden; I Kalies
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

5.  The place of surgery in the treatment of myasthenia gravis.

Authors:  K Fraser; J A Simpson; J Crawford
Journal:  Br J Surg       Date:  1978-05       Impact factor: 6.939

6.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

7.  Treatment of myasthenia gravis. Report on 139 patients.

Authors:  C Scoppetta; P Tonali; A Evoli; P David; F Crucitti; M L Vaccario
Journal:  J Neurol       Date:  1979       Impact factor: 4.849

8.  The value of thymectomy in myasthenia gravis: a computer-assisted matched study.

Authors:  J M Buckingham; F M Howard; P E Bernatz; W S Payne; E G Harrison; P C O'Brien; L H Weiland
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

9.  Thymectomy in the treatment of myasthenia.

Authors:  K Kunze
Journal:  Thorac Cardiovasc Surg       Date:  1980-12       Impact factor: 1.827

10.  Alternate-day prednisone: preliminary report of a double-blind controlled study.

Authors:  F M Howard; D D Duane; E H Lambert; J R Daube
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

View more
  24 in total

1.  The thymus in seronegative myasthenia gravis patients.

Authors:  N Willcox; M Schluep; M A Ritter; J Newsom-Davis
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

2.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment.

Authors:  N Sommer; B Sigg; A Melms; M Weller; K Schepelmann; V Herzau; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 3.  Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis.

Authors:  Kai Zhu; Jiaoxing Li; Xin Huang; Wei Xu; Weibin Liu; Jiaxin Chen; Pei Chen; Huiyu Feng
Journal:  Neurol Sci       Date:  2017-07-13       Impact factor: 3.307

Review 4.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

5.  Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.

Authors:  M J Kupersmith; G Ying
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  Repertoires of autoantibodies against homologous eye muscle in ocular and generalized myasthenia gravis differ.

Authors:  C W Zimmermann; F Eblen
Journal:  Clin Investig       Date:  1993-06

Review 7.  Medical and surgical treatment for ocular myasthenia.

Authors:  Michael Benatar; Henry Kaminski
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 8.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

9.  Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.

Authors:  Mark J Kupersmith
Journal:  J Neurol       Date:  2009-04-18       Impact factor: 4.849

10.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.